Kathryn Gregory has over 25 years of executive leadership experience in startup, mid-sized and large pharmaceutical and biotechnology companies. She has extensive experience in international business development including corporate strategy, licensing, mergers and acquisitions, alliance management and operational expertise in marketing, strategic sourcing and procurement.
Ms. Gregory is currently President of KG BioPharma Consulting LLC, a strategic advisory company, where she assists small and mid-size biopharma companies in a range of corporate strategy and business development activities. Concurrently, she is Head of Business Development at Rgenta Therapeutics, Inc., a small molecule RNA modulation company, and Chief Business Officer of reVision Therapeutics, Inc., a startup ophthalmology company. Previously, she was Vice President and Global Head of Business Development for Antengene Corporation, a hematology and oncology company focused on innovative medicines for patients in the Asia Pacific Region. Prior to Antengene, Ms. Gregory was Chief Business Officer of Aileron Therapeutics, a Boston-based oncology company. Earlier in her career, Ms. Gregory was Co-Founder and CEO for Seneb BioSciences, an early-stage, rare disease company which was acquired by a mid-sized biotech firm. Ms. Gregory also worked in senior roles at Purdue Pharma where she was responsible for business development for new therapeutic indications, and Shire Pharmaceuticals where she was responsible for business development for the Neuroscience and Ophthalmology business units.
Ms. Gregory received an M.B.A. from Pepperdine University and a B.A. degree from the University of California, Berkeley.